Latest Pseudomonas Stories
MARKHAM, ON, July 23 /PRNewswire-FirstCall/ - AlphaRx, Inc.
Infections of wounds, pneumonia, etc. in hospitals in particular are often caused by bacteria called Pseudomonas aeruginosa.
SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections.
Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF...
AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more availability than standard free drug in lung tissue, as demonstrated in a recent animal pharmacokinetic study. MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive treatment of...
An international team of scientists has discovered extensive similarities between a strain of bacteria commonly associated with plants and one increasingly linked to opportunistic infections in hospital patients.
Scottish and U.S.
First Diagnostic Test for Identifying E. coli, K. pneumoniae and P.
Dartmouth Medical School researchers have devised a novel approach for thwarting the relentless bacterial infections that thrive in the lungs of people with cystic fibrosis (CF), unlocking new possibilities against a tenacious and toxic hallmark of the common genetic disease.
Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients.
Pseudomonas aeruginosa is a common bacterium that can cause disease in animals and humans. It can be found in soil, water, skin flora, and most man-made environments throughout the world. It thrives in normal or hypoxic atmospheres; due to this it has colonized many natural and artificial environments. It can infect animals with damaged tissue or people with reduced immunity. Symptoms are generalized inflammation and sepsis. It can be fatal if colonization occurs in critical body organs,...
- To fire mitraille at.